-
Comparing the Recurrence Patterns of Reduced-Margins vs. RTOG-Protocol in Adjuvant Chemoradiation of High-Grade Gliomas: A Multicenter, Open-Label, Randomized Controlled Trial
CONCLUSION: Reducing the clinical target volume (CTV) margin from 2 cm to 1 cm in the adjuvant radiotherapy of high-grade gliomas did not significantly affect progression-free survival (PFS), overall survival (OS), or recurrence patterns. These findings support the feasibility and safety of margin reduction, even in settings where three-dimensional conformal radiotherapy (3D-CRT) is the primary… →
-
SSGJ-608 in moderate-to-severe plaque psoriasis: a multicenter, randomized, open-label, phase 3 study
CONCLUSIONS: SSGJ-608 was highly effective for treating patients with moderate-to-severe plaque psoriasis at 80mg Q2W and 160mg Q4W in a larger population, especially in patients previously treated with anti-IL-17 therapy, and exhibited a favorable tolerability profile in Chinese patients with moderate-to-severe plaque psoriasis. →
-
Clinical efficacy evaluation and economic analysis of regulating-yinyang moxibustion therapy for primary dysmenorrhea of cold induced blood stasis: a randomized controlled trial
CONCLUSION: Regulating-yinyang moxibustion therapy effectively alleviates pain and TCM syndromes in patients with PD of cold induced blood stasis, which may be related to the decrease of the contents of NGF and PGF2α in serum. This therapy shows its advantages in terms of health economics compared with the conventional gentle moxibustion therapy. →
-
Effect of pasteurized Akkermansia muciniphila MucT on insulin sensitivity, body composition, and GLP-1 production in subjects with metabolic syndrome: impact of low baseline gut Akkermansia levels
Pasteurized Akkermansia muciniphila MucT was found to improve barrier function in preclinical models and a proof-of-concept study in obese and prediabetic adults. Here, we describe the results of a double-blind placebo-controlled multicenter (Ireland and Germany) trial in 142 adults with metabolic syndrome, with or without prediabetes. The primary endpoint of whole-body insulin sensitivity (Matsuda index)… →
-
Long-term safety and efficacy of upadacitinib compared with adalimumab in patients with rheumatoid arthritis: 7-year data from the SELECT-COMPARE study
CONCLUSION: The safety profile of upadacitinib remained consistent with previous analyses, with no new safety concerns through 7 years. Upadacitinib and adalimumab (continuous or rescue treatment) maintained disease activity targets throughout the 7-year treatment period. Upadacitinib exhibited an acceptable benefit-risk profile for long-term RA treatment. →
-
Take 5: Career Advice from the Sports World
Few things in the world ignite our passion and unbridled joy like sports. We see this in scenes as far-flung as New York Knicks fans flooding the streets of Manhattan for days on end to celebrate the team’s first championship in more than a half century, to bleary-eyed Tunisian World Cup supporters cheering on their… →
-
Effect of a patient-driven perioperative intervention on health literacy: A stepped-wedge cluster randomised sub-study
We hypothesised that a patient-driven safety checklist would enhance patients’ health literacy. This study was conducted as a sub-study of a multicentre cluster trial with a stepped wedge design. Data were collected between March 2022 and February 2024. Healthcare personnel were partially blinded to group allocation and fully blinded to the health literacy questionnaire outcome.… →
-
Exploratory Clinical Trial of Honghua Xiaoyao Pills for the Treatment of Liver Depression and Haemostasis-Type Hyperplasia of Mammary Glands: A Single-Centre, Single-Arm Study
CONCLUSION: Honghua Xiaoyao pills are effective in reducing breast pain, shrinking breast masses and improving lower abdominal distension, breast distension, menstrual blood clots, chest tightness/discomfort and emotional symptoms in patients with liver depression and haemostasis-type HMG. →
-
Postoperative anlotinib plus radiotherapy in patients with newly diagnosed, unmethylated O6-methylguanine-DNA methyltransferase glioblastoma: A single-arm, phase 2 study
CONCLUSIONS: Postoperative anlotinib plus radiotherapy demonstrated clinically meaningful activity with a manageable safety profile in patients with unmethylated MGMT glioblastoma (Chinese Clinical Trials Registry identifier: ChiCTR2000040116). →
-
Asciminib Provides Better Efficacy and Favorable Safety and Tolerability Against Investigator-Selected Tyrosine Kinase Inhibitors in East Asian Patients With Newly Diagnosed Chronic Myeloid Leukemia: Results From a Subgroup Analysis of the Pivotal ASC4FIRST Study
ASC4FIRST (ClinicalTrials.gov NCT04971226) is a pivotal phase 3 clinical trial comparing the efficacy and safety of asciminib vs. standard of care (SoC) tyrosine kinase inhibitors (TKIs) in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP). The study demonstrated superior efficacy and a favorable safety profile for asciminib vs. all current SoC TKIs;… →
